Literature DB >> 12430852

Immunological reconstitution and immunoregulatory cells in hematopoietic stem cell transplantation.

Masahiro Imamura1.   

Abstract

Analysis of cytokine gene expression in peripheral blood mononuclear cells from patients received allogeneic hematopoietic stem cells transplantation (allo-SCT) showed that type 1 helper T cells (Th1)-derived cytokines increased in severe graft-versus-host disease (GVHD) while Th2-derived cytokines such as IL-4, IL-10, and IL-13 increased in mild GVHD. These results indicate that Th2 cells suppress GVHD although Thl cells augment GVHD. Chimerism analysis showed that mixed chimerism was often observed in younger (<30 years old) patients. Mixed chimerism in older (> or = 30 years old) patients were related to rejection and relapse while this situation is not the case in younger patients, thus indicating that mixed chimerism is an important prognostic factor in older patients. Among the chimerism of various cell populations, donor-derived CD56-positive cells are important in early engraftment when determined in allogeneic nonmyeloablative stem cell transplantation (allo-NST), regardless of the proportion of donor-derived CD3-positive cells. This result suggests that donor-derived CD56-positive cells are a more useful indicator for engraftment and rejection in early time period. Complementary-determining region 3 (CDR3) size spectratyping in T-cell receptor (TCR) chain subfamilies (V beta) showed that high level of diversity in TCR V beta repertoire is important for a late rejection and skewed TCR V repertoire is well correlated to occurrence of GVHD. Expression of inhibitory natural killer (NK) cell receptors such as CD158b and CD94/NKG2A on peripheral CD3-negative and positive cells were increased in parallel with GVHD. Interestingly, these molecules appeared to regulate GVHD while preserving graft-versus-leukemia (GVL) effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430852     DOI: 10.1007/bf03165243

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Increased proportion of HLA-class-I-specific natural killer cell receptors (CD94) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation.

Authors:  J Tanaka; Y Tutumi; L Zhang; A Mori; K Kahata; N Toyoshima; S Ohta; S Kobayashi; S Hashino; M Asaka; M Imamura
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

2.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.

Authors:  V M Braud; D S Allan; C A O'Callaghan; K Söderström; A D'Andrea; G S Ogg; S Lazetic; N T Young; J I Bell; J H Phillips; L L Lanier; A J McMichael
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

3.  The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease.

Authors:  J Tanaka; M Imamura; M Kasai; S Hashino; S Kobayashi; S Noto; T Higa; K Sakurada; M Asaka
Journal:  Bone Marrow Transplant       Date:  1997-03       Impact factor: 5.483

4.  Hematopoietic histoincompatibility reactions by NK cells in vitro: model for genetic resistance to marrow grafts.

Authors:  C Bordignon; J P Daley; I Nakamura
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

5.  Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status.

Authors:  J Gorski; M Yassai; X Zhu; B Kissela; B ] Kissella B [corrected to Kissela; C Keever; N Flomenberg
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

6.  Sequential analysis of HLA-C-specific killer cell inhibitory receptor (CD158b) expressing peripheral blood mononuclear cells during chronic graft-versus-host disease.

Authors:  J Tanaka; Y Tutumi; A Mori; S Ohta; S Kobayashi; M Asaka; M Imamura
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

7.  Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.

Authors:  J Dubovsky; H Daxberger; G Fritsch; D Printz; C Peters; S Matthes; H Gadner; T Lion; N Muller-Bérat
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

8.  Selective T-cell-receptor gene usage in allorecognition and graft-versus-host disease.

Authors:  K Yamanaka; W W Kwok; E M Mickelson; S Masewicz; F Smith; G T Nepom
Journal:  Transplantation       Date:  1993-05       Impact factor: 4.939

9.  Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.

Authors:  M Imamura; S Hashino; H Kobayashi; S Kubayashi; S Hirano; T Minagawa; J Tanaka; Y Fujii; M Kobayashi; M Kasai
Journal:  Bone Marrow Transplant       Date:  1994-06       Impact factor: 5.483

10.  Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation.

Authors:  A R Oberkircher; M P Strout; G P Herzig; P D Fritz; M A Caligiuri
Journal:  Bone Marrow Transplant       Date:  1995-11       Impact factor: 5.483

View more
  3 in total

Review 1.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

2.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Authors:  Mohamed L Sorror; Paul J Martin; Rainer F Storb; Smita Bhatia; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Christopher Davis; H Joachim Deeg; Stephanie J Lee; David G Maloney; Brenda M Sandmaier; Frederick R Appelbaum; Theodore A Gooley
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

Review 3.  New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.

Authors:  H Joachim Deeg
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.